Hierholzer J, Cordes M, Schelosky L, Sander B, Böck J C, David I, Horowski R, Poewe W
Strahlenklinik und Poliklinik, Klinikum Rudolf Virchow, Freie Universität Berlin.
Rofo. 1993 Jul;159(1):86-90. doi: 10.1055/s-2008-1032726.
The aim of our study was to compare the striatal dopamine D2-receptor density as measured by 123I-IBZM-SPECT with the results of the apomorphine-test. 30 patients were studied; 21 with idiopathic Parkinson's disease (IPD), 9 with Parkinson plus syndromes (PPS). Patients with IPD showed a significantly higher striatal IBZM binding as compared to patients with PPS (p = 0.006). A good correlation between IBZM binding and outcome of the apomorphine-test was found (p = 0.006). Low striatal IBZM binding indicates reduced dopamine D2-receptor density. This compromises successful dopaminergic medical therapy and is indicative of non-IPD disease. 123I-IBZM-SPECT could be diagnostic aid in the work-up of patients with extrapyramidal movement disorders. The response to dopaminergic drug treatment might be precluded by IBZM-SPECT in patients with Parkinsonian syndromes.
我们研究的目的是比较通过123I-碘苄胍单光子发射计算机断层扫描（123I-IBZM-SPECT）测量的纹状体多巴胺D2受体密度与阿扑吗啡试验的结果。研究了30名患者；其中21例为特发性帕金森病（IPD），9例为帕金森叠加综合征（PPS）。与PPS患者相比，IPD患者的纹状体IBZM结合显著更高（p = 0.006）。发现IBZM结合与阿扑吗啡试验结果之间存在良好的相关性（p = 0.006）。纹状体IBZM结合低表明多巴胺D2受体密度降低。这会影响多巴胺能药物治疗的成功，并提示非IPD疾病。123I-IBZM-SPECT可作为锥体外系运动障碍患者检查的诊断辅助手段。IBZM-SPECT可能会排除帕金森综合征患者对多巴胺能药物治疗的反应。
